Over-the-Counter (OTC) Pain Reliever, Cobroxin, to Be Featured on Lifetime Television Morning Show, The Balancing Act

XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be featured on a segment of The Balancing Act, a morning show that airs on the top-rated women’s cable television network, Lifetime Television.

"As the only morning show in the United States dedicated specifically to educating, inspiring and empowering women, The Balancing Act reaches an important segment of Cobroxin consumers,” commented Frank Rizzo, President and CEO of XenaCare Holdings. "We look forward to working closely with The Balancing Act's hosts, Beth Troutman and Kristy Villa, to help continue to educate viewers about Cobroxin and its added benefits over traditional pain relievers,” he concluded.

The upcoming segment, slated to air on May 17, 2010, and May 31, 2010, will feature an interview with Rik J Deitsch, the Chairman and CEO of Nutra Pharma Corporation (OTCBB: NPHC), the company that developed and currently manufactures Cobroxin. Additionally, it will explore the benefits to using Cobroxin and showcase testimonials from Cobroxin users.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an Advanced Oral Spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as an Advanced Topical Gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:

• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• Long Lasting

In 2009, XenaCare received the exclusive license from Nutra Pharma Corporation to market and distribute Cobroxin in the United States. XenaCare currently sells Cobroxin in food and drugstores nationwide, including:

*Available by May 1, 2010

Due to some housekeeping items, management has chosen to file for automatic extension for filing of the Form 10-K, 12-31-09.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin, for the treatment of moderate to severe (Stage 2) chronic pain, the Company’s clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. In addition, the company offers formulations for the lifestyle performance market, which consists of a sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet as well as pharmacies. The company was founded in 2001 and is based in Delray Beach, Florida.

http://www.XenaCareHoldings.com

http://www.Cobroxin.com

Cautionary Note Concerning Forward Looking Statements

Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans for specific advertising and marketing campaigns supporting Cobroxin are forward looking statement and subject to change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.